Subscribe
gutzemberg
gutzemberg / iStockphoto.com
26 July 2017Americas

Life sciences companies face off over ‘Juno’ trademark

Clinical-stage biotech company Juno Therapeutics has not taken kindly to another business using its name.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Kite accused of infringing Juno’s cancer immunotherapy
5 September 2017   Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

More on this story

Americas
Kite accused of infringing Juno’s cancer immunotherapy
5 September 2017   Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

More on this story

Americas
Kite accused of infringing Juno’s cancer immunotherapy
5 September 2017   Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler